Prevention of thrombosis in polycythemia vera and essential thrombocythemia

Haematologica

Volumn 93, Issue 3, 2008, Pages 331-335

  Landolfi, Raffaele ^a,b,c   Di Gennaro, Leonardo ^a  

^a Haemostasis Research Center

^b OASI RESEARCH INSTITUTE IRCCS   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANAGRELIDE; CLOPIDOGREL; DIPYRIDAMOLE; HYDROXYUREA; INTERFERON; JANUS KINASE 2; PLACEBO;

CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; GENE MUTATION; HUMAN; LEUKOCYTE COUNT; LOW DRUG DOSE; PHLEBOTOMY; POLYCYTHEMIA VERA; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; THROMBOCYTE COUNT; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSIENT ISCHEMIC ATTACK; TREATMENT PLANNING; VENOUS THROMBOEMBOLISM;

ARTERIAL OCCLUSIVE DISEASES; ASPIRIN; DIPYRIDAMOLE; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYUREA; JANUS KINASE 2; MULTICENTER STUDIES AS TOPIC; PHLEBOTOMY; POLYCYTHEMIA VERA; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; THROMBOCYTHEMIA, HEMORRHAGIC; THROMBOPHILIA; THROMBOSIS; TICLOPIDINE; VENOUS THROMBOSIS;

EID: 40849113039     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12604     Document Type: Review

References (30)

1. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350:114-24.
2. Streiff MB, Smith B, Spivak JL. The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members' practice patterns. Blood 2002;99:1144-9.
3. De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, et al. for the GIMEMA CMD-Working Party. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 2008; 93:372-80.
4. Spivak JL, Barosi G, Tognoni G, Barbui T, Finazzi G, Marchioli R, et al. Chronic myeloproliferative disorders. Hematology Am Soc Hematol Educ Program 2003;200-24.
5. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005;128:275-90.
6. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97.
7. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90.
8. Wolanskyj AP, Lasho TL, Schwager SM, McClure RF, Wadleigh M, Lee SJ, et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005;131:208-13
9. Kittur J, Knudson RA, Lasho TL, Finke CM, Gangat N, Wolanskyj AP, et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 2007;109:2279-84.
10. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005;366:1945-53.
11. Finazzi G, Barbui T. How I treat patients with polycythemia vera. Blood 2007;109:5104-11.
12. Gangat N, Wolanskyj AP, McClure RF, Li CY, Schwager S, Wu W, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia 2007;21:270-6.
13. Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005;23:2224-32.
14. Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors and Jak2 mutation status. Blood 2007;109:2310-3.
15. Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 2007;109:2446-52.
16. Watson KV, Key N. Vascular complications of essential thrombocythaemia: a link to cardiovascular risk factors. Br J Haematol 1993;83:198-203.
17. Di Nisio M, Barbui T, Di Gennaro L, Borrelli G, Finazzi G, Landolfi R, et al. The haematocrit and platelet target in polycythemia vera. Br J Haematol 2007;136:249-59.
18. Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005;353:2373-83.
19. Chan FKL, Ching JYL, Hung LCT, Wong VWS, Leung VKS, Kung NNS, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005;352:238-44.
20. Liberopoulos EN, Elisaf MS, Tselepis AD, Archimandritis A, Kiskinis D, Cokkinos D, et al. Upper gastrointestinal haemorrhage complicating antiplatelet treatment with aspirin and/or clopidogrel: where we are now? Platelets 2006;17:1-6.
21. Ramanath VS, Eagle KA. Evidence-based medical therapy of patients with acute coronary syndromes. Am J Cardiovasc Drugs 2007;7:95-116.
22. Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) trial. Circulation 2004;110:1202-8.
23. ESPRIT Study Group, Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomized controlled trial. Lancet 2006 20;367:1665-73.
24. Ariesen MJ, Algra A, Kappelle LJ. Antiplatelet drugs in the secondary prevention after stroke: differential efficacy in large versus small vessel disease? A subgroup analysis from ESPS-2. Stroke 2006;37:134-8.
25. Landolfi R, Ciabattoni G, Patrignani P, Castellana MA, Pogliani E, Bizzi B, Patrono C. Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. Blood 1992;80:1965-7.
26. Rocca B, Ciabattoni G, Tartaglione R, Cortelazzo S, Barbui T, Patrono C, Landolfi R. Increased thromboxane biosynthesis in essential thrombocythemia. Thromb Haemost 1995;74:1225-30.
27. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al. United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33-45.
28. Evangelista V, Manarini S, Dell'Elba G, Martelli N, Napoleone E, Di Santo A, et al. Clopidogrel inhibits platelet-leukocyte adhesion and platelet-dependent leukocyte activation. Thromb Haemost 2005;94:568.
29. Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 2005;33:523-30.
30. Falanga A, Marchetti M, Evangelista V, Vignoli A, Licini M, Balicco M, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000;96:4261-6.